cvs caremark glp-1 news faces class-action lawsuit over Zepbound, Wegovy coverage CVS Is Dropping Zepbound. Here

Key Takeaways Retatrutide (LY3437943) is an investigational weight loss medication developed by Eli Lilly Triple-agonist mechanism: First drug to activate GLP-1, GIP, and glucagon receptors simultaneously Phase 2 results: Up to 24.2% weight loss at 48 weeks (approximately 58 lbs for a 240-lb person) Not FDA-approved: Currently in Phase 3 clinical trials, expected approval in 20272028 How it differs: Outperforms semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) in weight loss trials Access now: Clinical trials (free), compounding pharmacies, or research peptide vendors What Is Retatrutide

Even though your diet should provide these, its difficult to guarantee regular intake of all the necessary nutrients

However, significant cost, access, and sustainability challenges must be addressed for broader population-level impact

Standard tirzepatide starts at 2.5 mg and climbs to 15 mg

Consider Them Served by Hum Nutrition Shiri Feldman Jun 25, 2025 2 min read New Flatter Me Fiber Flavor Mixes Science with a Side of Vacation What do you get when you mix clinical research, a tropical twist, and a craving-curbing fiber that works in 30 minutes

As appetite suppression kicks in, share of stomach becomes a fierce battle, explains Ellis